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Objective
To evaluate efficacy and safety of Anakinra in SoJIA non
responsive to antiTNF.
Introduction
TNF-inhibitors have demonstrated a favourable benefit-
to-risk profile. Intolerance, lost of efficacy or adverse
events led to other options as the antagonist of the IL-1
receptor (Anakinra), in SoJIA.
206 pts were treated with TNF inhibitors; 45 patients
(22%) were affected by SoJIA.
Methods
Sixteen patients affected by SoJIA (12 F, 4 M) were
switched to Anakinra. Patients received Anakinra (in asso-
ciation with MTX) at the dose of 100 mg daily (> 50 kg)
or at the dose of 1–2 mg/kg daily (< 50 kg). All patients
failed previous DMARDS and TNF inhibitors. Paediatric
patients were evaluated according to the ACR30 paediatric
criteria. Adults were evaluated according to EULAR criteria
(DAS). We also considered clinical parameters as fever,
rash, adenopathy and organomegaly.
Results
Median age 16 years (9.4–47.2); median duration of the
disease 14.5 years (0.5–44.3); mean duration of therapy 1
year (0.08–4.3). 11/16 patients (69%) were responders.
5/16 patients (31%) suspended for adverse events and/or
inefficacy. The most important adverse event was the
intensive pain on the injection site and a severe cutaneous
reaction. Responders reduced or suspended prednisone
and NSAIDS. Systemic symptoms like spiking fever and
rash had an immediate improvement. In 3 patients Anak-
inra was efficacious in renal amiloidosis as well.
Conclusion
Anakinra plus MTX showed a good efficacy and safety in
short and medium term treatment of long lasting refrac-
tory systemic JIA. A controlled multicenter clinical trial is
needed.
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